Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2013196 | 0.84 | HCRTR1 (0.42) | HCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL13138972 | 0.84 | HCRTR1 (0.50) | HCRTR1HCRTR2KMT2ASMN1; SMN2 | |
| SCHEMBL13138970 | 0.82 | KMT2A (0.55) | EPHX2HCRTR1HCRTR2KMT2AALOX15 | |
| SCHEMBL13138994 | 0.82 | KMT2A (0.55) | EPHX2HCRTR1HCRTR2KMT2AALOX15 | |
| SCHEMBL2012684 | 0.82 | HCRTR1 (0.42) | HCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL13138950 | 0.80 | HCRTR1 (0.43) | HCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL13138975 | 0.80 | HCRTR1 (0.50) | HCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL2012172 | 0.79 | HCRTR2 (0.47) | EPHX2HCRTR1HCRTR2KMT2AALOX15 | |
| SCHEMBL13139051 | 0.79 | HCRTR1 (0.47) | HCRTR1HCRTR2KMT2ASMN1; SMN2 | |
| SCHEMBL2012170 | 0.79 | HCRTR2 (0.47) | EPHX2HCRTR1HCRTR2KMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011073316-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2011-06-23 | — | — | WO | disclosed |